The Ann Arbor, Michigan-based firm will compete with a few well-established players offering systems that can run in vitro diagnostic tests as well as lab-developed tests. 

A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.

The company is continuing to collect utility and cost effectiveness data for its SelectMDx test in reducing unnecessary procedures in men with signs of a possible prostate cancer.

The firm's nanotechnology-enabled, AI-based, machine learning tool identifies biomarkers in blood samples and produces results in 10 to 30 seconds.

A record pace of hospital mergers, including 115 in 2017, has the potential to alter the laboratory competitive landscape, consultants say.